JAMA Neurology

06/24/2026

Among patients with familial or sporadic , cerebrospinal fluid TMEM106B levels were lower with greater disease severity, progression, smaller brain volumes, and in carriers of the protective rs1990622 genotype.

https://ja.ma/4vXWFUm

06/23/2026

A patient with isolated peripheral nerve vasculitis developed reversible bilateral hypoglossal palsy and tongue atrophy, with resolution of bulbar symptoms following immunosuppressive therapy and reinnervation, a rare neurological outcome.

https://ja.ma/4g0Gt0b

06/22/2026

💬 Perspective from JAMA: Monoclonal antibodies for clear brain amyloid-β and modestly slow cognitive decline in early stages, supporting a causal role but with clinically limited impact and risk for imaging abnormalities.

https://ja.ma/3QB5Mvp

06/22/2026

Among patients with familial or sporadic , cerebrospinal fluid TMEM106B levels were lower with greater disease severity, progression, smaller brain volumes, and in carriers of the protective rs1990622 genotype.

https://ja.ma/4vnIkAM

06/22/2026

Machine learning analysis of patient-clinician conversations identified cognitive impairment with sensitivity 68% and specificity 64%, supporting passive speech-based screening in routine .

https://ja.ma/49YDYYn

06/20/2026

Machine learning analysis of patient-clinician conversations identified cognitive impairment with sensitivity 68% and specificity 64%, supporting passive speech-based screening in routine .

https://ja.ma/4xv3caV

06/19/2026

💬 Editorial: Routine clinical conversations in contain acoustic signals that machine learning models can use for passive cognitive impairment screening, but risks and potential biases must be evaluated before clinical adoption.

https://ja.ma/4fW5WHZ

06/19/2026

In a prospective cohort study from Liberia, adult Ebola virus disease ( ) survivors experienced a broad spectrum of neurological symptoms—including memory loss, headaches, depression, and sleep disturbances—at significantly higher rates than control individuals for more than 7 years after infection.

Most neurological findings improved over time, but persistent symptoms such as memory loss and concentration difficulties remained common. These results underscore the need for long-term neurological follow-up and multidisciplinary care to address ongoing neurocognitive and functional challenges after Ebola.

https://ja.ma/4xyaxGB

06/18/2026

Congratulations to JAMA Neurology Editor in Chief S. Andrew Josephson, MD, on his appointment as Dean of the UCSF School of Medicine.

Previously, Dr Josephson led UCSF's top-ranked Department of Neurology. Since becoming Editor in Chief of JAMA Neurology in 2013, he has advanced the science and practice of neurology through rigorous scholarship and clinical insight.

We congratulate Dr Josephson on this distinguished appointment and look forward to his continued contributions to medicine.

https://www.ucsf.edu/news/2026/06/432091/andy-josephson-new-dean-ucsf-school-of-medicine?utm_source=ucsf&utm_medium=li&utm_campaign=SOM_announcement

06/18/2026

IL-6 receptor blockers provided favorable recovery and visual improvement after acute attacks in and , but controlled trials are needed to determine effects on long-term disability.

This case series describes multicenter experience with interleukin 6 (IL-6) receptor blockers used during attacks in aquaporin 4–immunoglobulin G–positive neuromyelitis optica spectrum disorder (AQP4+NMOSD) and myelin oligodendrocyte glycoprotein antibody–associated disease (MOGAD).